Anika Therapeutics (ANIK) Amortization of Deferred Charges (2021 - 2026)

Anika Therapeutics (ANIK) has 6 years of Amortization of Deferred Charges data on file, last reported at $464000.0 in Q1 2026.

• On a quarterly basis, Amortization of Deferred Charges fell 19.58% year-over-year to $464000.0 in Q1 2026; TTM through Mar 2026 was $1.9 million, a 9.9% decrease from a year earlier, with the FY2025 full-year figure at $2.1 million, down 4.14% from the prior year.
• Amortization of Deferred Charges for Q1 2026 stood at $464000.0, down from $499000.0 in the prior quarter.
• Over the last five years, Amortization of Deferred Charges for ANIK reached as high as $598000.0 in Q4 2023 and fell as low as $394000.0 in Q2 2022.
• Historically, Amortization of Deferred Charges has averaged $515058.8 across 5 years, with a median of $528000.0 in 2022.
• Across the five-year window, Amortization of Deferred Charges surged 38.07% in 2023 and decreased 24.63% in 2024, its largest moves.
• Year by year, Amortization of Deferred Charges stood at $528000.0 in 2022, then grew by 13.26% to $598000.0 in 2023, then slipped by 1.51% to $589000.0 in 2024, then fell by 15.28% to $499000.0 in 2025, then retreated by 7.01% to $464000.0 in 2026.
• Per Business Quant data, the three most recent Amortization of Deferred Charges figures were $464000.0 in Q1 2026, $499000.0 in Q4 2025, and $495000.0 in Q3 2025.